Risk-Adapted Therapy for Pediatric Hodgkin's Disease

Trial Information

Risk-Adapted Therapy for Pediatric Hodgkin's Disease

This study will evaluate the following objectives:

Primary Objectives:

1. To evaluate the efficacy of 4 cycles of VAMP chemotherapy alone in patients with
favorable risk Hodgkin's disease who achieve a complete response after 2 cycles of VAMP
chemotherapy.

2. To evaluate the efficacy of 4 cycles VAMP chemotherapy plus low dose RT in patients
with favorable risk Hodgkin's disease who achieve a partial response after 2 cycles of
VAMP chemotherapy.

3. To evaluate the efficacy of 2 alternating cycles of VAMP/COP chemotherapy (total 4
cycles of chemotherapy) plus low-dose, involved-field RT in children with intermediate
risk Hodgkin's disease.

4. To evaluate the efficacy of 12 weeks of Stanford V chemotherapy plus low-dose,
involved-field RT in children with unfavorable risk Hodgkin's disease.

Secondary Objectives:

1. To evaluate patient quality of life during and after treatment from the patient and
parent perspective.

2. To compare patient and parental ratings of treatment-related symptoms and patient
physical, psychological, social and cognitive functioning before the first treatment
(T1 - baseline); after Cycle 2 or after 8 weeks of Stanford V (T2 - Evaluate Response);
after cycle 4 or after 12 weeks of Stanford V and before or on the first day of
radiation (as applicable) (T3); at the conclusion of radiation or within a few days
following the end of radiation (as applicable) (T4); and at 3 to 6 months after
completion of therapy follow-up evaluation (T5).